In conclusion, while enhancing HDL-C levels has thus far yielded disappointing results in mitigating CVD risk, both niacin and novel agents such as CETP inhibitors and rHDL particles may still hold promise for improving other aspects of human health, such as inflammatory conditions, metabolic syndrome, and cancer. This evidence concerns the gene CETP and cancer.